Moderna and merck announce mrna-4157 (v940) in combination with keytruda(r) (pembrolizumab) demonstrated a statistically significant and clinically meaningful improvement in distant metastasis-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus keytruda
Mrna-4157 (v940) in combination with keytruda reduced the risk of distant metastasis or death by 65% (hr=0.347 [95% ci, 0.145-0.828]); one-sided p value=0.0063) compared to keytruda alone the dmfs results, a key secondary endpoint of the phase 2b keynote-942 study, will be presented at the 2023 american society of clinical oncology (asco) annual meeting companies plan to initiate a phase 3 study in the adjuvant setting in patients with high-risk melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer cambridge, ma and rahway, nj / accesswire / june 5, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside of the united states and canada, today announced distant metastasis-free survival (dmfs) results from the phase 2b randomized keynote-942/mrna-4157-p201 study, a clinical trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv). in the overall intention-to-treat (itt) population, adjuvant treatment with mrna-4157 (v940) in combination with keytruda demonstrated a statistically significant and clinically meaningful improvement in dmfs, a key secondary endpoint of the study, compared with keytruda alone and reduced the risk of developing distant metastasis or death by 65% (hr=0.347 [95% ci, 0.145-0.828]); one-sided p value=0.0063).
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission